Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG

This study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF<sup>®</sup>01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated i...

Full description

Bibliographic Details
Main Authors: Sergi López-Serrano, Lorena Cordoba, Mónica Pérez-Maillo, Patricia Pleguezuelos, Edmond J. Remarque, Thomas Ebensen, Carlos A. Guzmán, Dennis Christensen, Joaquim Segalés, Ayub Darji
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/9/7/751
id doaj-ddf9ff625de74314839de7aca4cf5aa7
record_format Article
spelling doaj-ddf9ff625de74314839de7aca4cf5aa72021-07-23T14:10:41ZengMDPI AGVaccines2076-393X2021-07-01975175110.3390/vaccines9070751Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEGSergi López-Serrano0Lorena Cordoba1Mónica Pérez-Maillo2Patricia Pleguezuelos3Edmond J. Remarque4Thomas Ebensen5Carlos A. Guzmán6Dennis Christensen7Joaquim Segalés8Ayub Darji9IRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainBiomedical Primate Research Center, Department of Immunobiology, P.O. Box 3306, 2280 GH Rijswijk, The NetherlandsHelmholtz Centre for Infection Research, Department of Vaccinology and Applied Microbiology, Inhoffenstraße 7, 38124 Braunschweig, GermanyHelmholtz Centre for Infection Research, Department of Vaccinology and Applied Microbiology, Inhoffenstraße 7, 38124 Braunschweig, GermanyVirus Research and Development Laboratory, Department of Virus and Microbiological Special Diagnostics, Statens Serum Institute, Artillerivej 5, 2300 Copenhagen, DenmarkIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainThis study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF<sup>®</sup>01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated intramuscularly twice with either NG34 + CAF<sup>®</sup>01 or NG34 + CDA/αGCM. As controls, groups of animals (<i>n</i> = 6 or 4) either non-vaccinated or vaccinated with human seasonal trivalent influenza vaccine or NG34 + Freund’s adjuvant were included in the study. All animal groups were challenged with the 2009 pandemic (pdm09) strain of H1N1 (total amount of 7 × 10<sup>6</sup> TCID<sub>50</sub>/mL) via intranasal and endotracheal routes 21 days after second vaccination. Reduced consolidated lung lesions were observed both on days three and seven post-challenge in the animals vaccinated with NG34 + CAF<sup>®</sup>01, whereas higher variability with relatively more severe lesions in pigs of the NG34 + CDA/αGCM group on day three post-infection. Among groups, animals vaccinated with NG34 + CDA/αGCM showed higher viral loads in the lung at seven days post infection whereas animals from NG34 + CAF<sup>®</sup>01 completely abolished virus from the lower respiratory tract. Similarly, higher IFNγ secretion and stronger IgG responses against the NG34 peptide in sera was observed in animals from the NG34 + CAF<sup>®</sup>01 group as compared to the NG34 + CDA/αGCM. NG34-vaccinated pigs with adjuvanted CAF<sup>®</sup>01 or CDA/αGCM combinations resulted in different immune responses as well as outcomes in pathology and viral shedding.https://www.mdpi.com/2076-393X/9/7/751vaccineadjuvantsinfluenzaimmunitypathology
collection DOAJ
language English
format Article
sources DOAJ
author Sergi López-Serrano
Lorena Cordoba
Mónica Pérez-Maillo
Patricia Pleguezuelos
Edmond J. Remarque
Thomas Ebensen
Carlos A. Guzmán
Dennis Christensen
Joaquim Segalés
Ayub Darji
spellingShingle Sergi López-Serrano
Lorena Cordoba
Mónica Pérez-Maillo
Patricia Pleguezuelos
Edmond J. Remarque
Thomas Ebensen
Carlos A. Guzmán
Dennis Christensen
Joaquim Segalés
Ayub Darji
Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG
Vaccines
vaccine
adjuvants
influenza
immunity
pathology
author_facet Sergi López-Serrano
Lorena Cordoba
Mónica Pérez-Maillo
Patricia Pleguezuelos
Edmond J. Remarque
Thomas Ebensen
Carlos A. Guzmán
Dennis Christensen
Joaquim Segalés
Ayub Darji
author_sort Sergi López-Serrano
title Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG
title_short Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG
title_full Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG
title_fullStr Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG
title_full_unstemmed Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG
title_sort immune responses to pandemic h1n1 influenza virus infection in pigs vaccinated with a conserved hemagglutinin ha1 peptide adjuvanted with caf<sup>®</sup>01 or cda/αgalcermpeg
publisher MDPI AG
series Vaccines
issn 2076-393X
publishDate 2021-07-01
description This study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF<sup>®</sup>01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated intramuscularly twice with either NG34 + CAF<sup>®</sup>01 or NG34 + CDA/αGCM. As controls, groups of animals (<i>n</i> = 6 or 4) either non-vaccinated or vaccinated with human seasonal trivalent influenza vaccine or NG34 + Freund’s adjuvant were included in the study. All animal groups were challenged with the 2009 pandemic (pdm09) strain of H1N1 (total amount of 7 × 10<sup>6</sup> TCID<sub>50</sub>/mL) via intranasal and endotracheal routes 21 days after second vaccination. Reduced consolidated lung lesions were observed both on days three and seven post-challenge in the animals vaccinated with NG34 + CAF<sup>®</sup>01, whereas higher variability with relatively more severe lesions in pigs of the NG34 + CDA/αGCM group on day three post-infection. Among groups, animals vaccinated with NG34 + CDA/αGCM showed higher viral loads in the lung at seven days post infection whereas animals from NG34 + CAF<sup>®</sup>01 completely abolished virus from the lower respiratory tract. Similarly, higher IFNγ secretion and stronger IgG responses against the NG34 peptide in sera was observed in animals from the NG34 + CAF<sup>®</sup>01 group as compared to the NG34 + CDA/αGCM. NG34-vaccinated pigs with adjuvanted CAF<sup>®</sup>01 or CDA/αGCM combinations resulted in different immune responses as well as outcomes in pathology and viral shedding.
topic vaccine
adjuvants
influenza
immunity
pathology
url https://www.mdpi.com/2076-393X/9/7/751
work_keys_str_mv AT sergilopezserrano immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
AT lorenacordoba immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
AT monicaperezmaillo immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
AT patriciapleguezuelos immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
AT edmondjremarque immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
AT thomasebensen immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
AT carlosaguzman immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
AT dennischristensen immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
AT joaquimsegales immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
AT ayubdarji immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg
_version_ 1721285562239811584